Peroxisome proliferator-activated receptor-γ2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2

Journal of Hypertension

Volumn 23, Issue 2, 2005, Pages 301-308

  Gouni Berthold, Ioanna ^a   Giannakidou, Eleni ^a   Müller Wieland, Dirk ^b   Faust, Michael ^a   Kotzka, Jörg ^b   Berthold, Heiner K ^c   Krone, Wilhelm ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c German Medical Association   (Germany)

Author keywords

Diabetes mellitus type 2; ENOS; Hypertension; Polymorphism; PPAR 2

Indexed keywords

ALANINE; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TRIACYLGLYCEROL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHI SQUARE TEST; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENOTYPE; GERMANY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 14044268174     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200502000-00012     Document Type: Article

References (77)

1. Wilson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550.
2. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101:1311-1318.
3. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent PPARgamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153:17-23.
4. Marx N, Schoenbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83:1097-1103.
5. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARgamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8:1224-1234.
6. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPARgamma) gene: alternative promotor use and different splicing yield two mPPARgamma isoforms. Proc Natl Acad Sci USA 1995; 92:7921-7925.
7. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 2004; 272:18779-18789.
8. Vidal-Puig AJ, Considione RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99:2416-2422.
9. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma; implications for cardiovascular disease. Hypertension 2004; 43:297-305.
10. Roberts AW, Thomas A, Rees A, Evans M. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 2003; 14:567-573.
11. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor gamma2 pro12ala polymorphism. Diabetes 2002; 51:2341 -2347.
12. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241:270-274.
13. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, et al. Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 1998; 47:490-492.
14. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12Ala substitution in PPARgamma is associated with resistance to development of diabetes in the general population; possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50:891-894.
15. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:002-012.
16. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48:489-509.
17. Radomski MW, Salas E. Nitric oxide-biological mediator, modulator and factor of injury; its role in the pathogenesis of atherosclerosis. Atherosclerosis 1995; 118:369-380.
18. Haynes DG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993; 11:1375-1380.
19. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93:13176-13181.
20. Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 2000; 70:241-251.
21. Poirier O, Mao C, Mallet C, Nicaud V, Herrmann SM, Evans A, et al. Polymorphisms of the endothelial nitric oxide synthase gene-no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 2000; 29:284-290.
22. Kunnas TA, Ilveskoski E, Niskakangas T, Laippala E, Kajander OA, Mikkelson J, et al. Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 2002; 80:605-609.
23. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000; 471:45-50.
24. Komatsu M, Kawagishi T, Emoto M, Shoji T, Yamada A, Sato K, et al. ecNOS gene polymorphism is associated with endothelium-dependent vasodilation in type 2 diabetes. Am J Physiol Heart Circ Physiol 2002; 283:H557-H561.
25. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2:41-46.
26. Ichihara S, Yamada Y, Fujimura T, Nakashima N, Yokota M. Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction. Am J Cardiol 1998; 81:83-86.
27. Cine M, Hatemi AC, Erginel-Unaltuna N. Association of a polymorphism of the ecNOS gene with myocardial infarction in a subgroup of Turkish MI patients. Clin Genet 2002; 61:66-70.
28. Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK, et al. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999; 116:880-886.
29. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998; 32:521-526.
30. Pulkkinen A, Viitanen L, Kareinen A, Lehto S, Vauhkonen I. Laakso M. Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J Mol Med 2000; 78:372-379.
31. Sigusch HH, Surber R, Lehmann MH, Surber S, Weber J, Henke A, et al. Lack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. Scand J Clin Lab Invest 2000; 60:229-235.
32. Granath B, Taylor R, Bockxmeer FM, van Mamotte CD. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J Cardiovasc Risk 2001; 8:499-502.
33. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287.
34. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator - activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268:178-182.
35. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Volund A, et al. Impact of two common polymorphisms in the PPArgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic tweens: thrifty genotype, thrifty phenotype, or both? Diabetes 2003; 52:194-198.
36. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARg Pro12ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
37. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271:212-216.
38. Lindi VI, Uusitupa MIJ, Lindström J, Louheranta A, Eriksson JG, Valle TT, et al. Association of the Pro12ala polymorphism in the PPAR-gamma2 gene with 3 year incidence of type 2 diabetes and body weight change in the Finnish diabetes prevention study. Diabetes 2002; 51:2581-2586.
39. Gonzalez Sanchez J, Serrano Rios M, Fernandez Perez C, Laakso M, Martinez Larrad MT. effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002; 147:495-501.
40. Kadowaki T, Hara K, Kubbota N, Tobe K, Terauchi Y, Yamauchi T, et al. The role of PPARgamma in high-rat diet-induced obesity and insulin resistance. J Diabetes Complicat 2002; 16:41-45.
41. Lei HH, Chen MH, Yang WS, Chiu MC, Chen MC, Tai TY, et al. Peroxisome proliferator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000; 49:1267-1270.
42. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes 2000; 24:195-199.
43. Rosmond R, Chagnon M, Bouchard C. The Pro12ala PPARgamma2 gene missense mutation is associated with obesity and insulin resistance in Swedish middle-aged men. Diabetes Metab Res Rev 2003; 19:159-163.
44. Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor gamma 2 is associated with combined hyperlipidemia in obesity. Eur J Endocrinol 2001; 144:277-282.
45. Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, Schaffer A. A Pro12Ala polymorphism on the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male Caucasian type 2 diabetes patients. Exp Clin Endocrinol Diab 2002; 110:60-66.
46. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47:1806-1808.
47. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BediaM) study. Diabetes 2002; 51:2653-2657.
48. Clement K, Hercberg S, Psiinge B, Galan P, Varroud-vial M, Shuldiner AR, et al. The Pro115Gln and Pro12Ala PPARgamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000; 24:391-393.
49. Hamann A, Munzberg H, Buttronn P, Busing B, Hinney A, Mayer H, et al. Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. Eur J Endocrinol 1999; 141:90-92.
50. Mancini FP, Vaccaro O, Sabatini L, Tufano A, Rivellese AA, Riccardi G, et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999; 48:1466-1468.
51. Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, et al. Significance of Pro12Ala mutation in peroxisomeproliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000; 85:1801-1804.
52. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Com 1999; 254:450-453.
53. Memisoglou A, Hankinson S, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome proliferator- activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 2002; 12:597-603.
54. Schaffler A, Barth N, Schmitz G, Zietz B, Palitzsch KD, Scholmerich J. Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine 2001; 14:369-373.
55. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus ADA. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998; 22(Suppl 1): S5-S19.
56. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method (Statistical notes). BMJ 1995; 310:170.
57. Sutton J, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25:058-064.
58. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51:314-317.
59. Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F. Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertension. J Hypertens 2003; 21:1649-1655.
60. Östgren CJ, Lindblad U, Melander O, Melander A, Groop L, Rastam L. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes project. J Hypertens 2003; 21:1657-1662.
61. Haastedt SJ, Ren QF, Teng K, Elbein SC. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001; 86:536-541.
62. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, et al. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 2001; 50:886-890.
63. Ksiazek P, Wojewoda P, Muc K, Butaczynska M. Endothelial nitric oxide synthase gene intron 4 polymorphism in type 2 diabetes mellitus. Mol Diagn 2003; 7:119-123.
64. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998; 11:125-128.
65. Shoji M, Tsutaya S, Saito R, Takamatu H, Yasujima M. Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci 2000; 65:2557-2562.
66. Yokoyama K, Tsukada T, Nakayama M, Hara S, Yamada A, Kawaguchi Y, et al. An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate volume-dependent hypertension in patients on hemodialysis. Nephron 2000; 85:232-237.
67. Hirschhorn JN, Altshuler D. Once and again-issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002; 87:4438-4441.
68. Deinum J. Finding hypertension genes: urge for more. J Hypertens 2003; 21:1611-1612.
69. Cleland SJ. A fundamental and novel insight into the pathophysiology of hypertension or just another dubious genetic association study? J Hypertens 2003; 21:1613-1614.
70. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003; 52:3010-3013.
71. Poirier O, Nicaud V, Cambien F, Tiret L. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis research study II. J Mol Med 2000; 78:346-351.
72. Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, et al. Studies of the Pro12ala polymorphism of the PPARgamma gene in the Danish MONICA cohort: homozygosity of the Ala-allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87:3989-3992.
73. Chuang LM, Hsuing CA, Chen YD, Ho LT, Sheu WH, Pei D, et al. Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIR study. J Mol Med 2001; 79:656-664.
74. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Valiance P, et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 2001; 38:1054-1061.
75. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 245:190-193.
76. Wang XL, Mahaney MC, Sim AS, Wang J, Blangero J, Almasy L, et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscl Thromb Vasc Biol 1997; 17:147-153.
77. Kunnas TA, Lehtimäki T, Laaksonen R, Ilveskoski E, Janatuinen T, Vesalainen R, et al. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin. A placebo-controlled PET study. J Mol Med 2002; 80:802-807.